RecruitingNCT07067983
Clinical Evaluation of GRAPE Model for Gastric Cancer Screening
Sponsor
Zhejiang Cancer Hospital
Enrollment
1,000,000 participants
Start Date
May 30, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
A Prospective Study Evaluating the Performance of the GRAPE Model in Gastric Cancer Screening and Its Detection Rates Across Different Disease Stages
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Plain Language Summary
Simplified for easier understanding
This study is testing an AI-based screening model called GRAPE that can analyze routine CT scan images to identify patterns that may indicate gastric cancer (stomach cancer) — potentially detecting it earlier than current methods, even when the CT scan was ordered for other reasons. Early detection of stomach cancer significantly improves treatment outcomes.
**You may be eligible if...**
- You are 18 to 80 years old
- You are already scheduled to have a chest or abdominal CT scan for any reason
- You are willing to participate and sign a consent form
**You may NOT be eligible if...**
- You have already been diagnosed with gastric (stomach) cancer
- You have severe intellectual disabilities or communication difficulties that prevent you from understanding or participating in the study
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIAGNOSTIC_TESTResults following systematic screening
The GRAPE model's output (positive or negative) determines whether patients require follow-up gastroscopy
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07067983
Related Trials
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
NCT045579691 location
Lead-212 PSV359 Therapy for Patients With Solid Tumors
NCT067107567 locations
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
NCT0614703715 locations
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT0671013281 locations
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
NCT028388361 location